FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2325814882> ?p ?o ?g. }

• W2325814882 endingPage "1465" @default.
• W2325814882 startingPage "1460" @default.
• W2325814882 abstract "Purpose To examine 10-year rates of local, regional, and distant recurrences, patterns of recurrence, and survival rates for breast cancer patients enrolled on Study NRG Oncology/Radiation Therapy Oncology Group 9517, a multi-institutional prospective trial that studied one of the earliest methods of accelerated partial breast irradiation (APBI), multicatheter brachytherapy (MCT). Methods and Materials Eligibility included stage I/II unifocal breast cancer <3 cm in size after lumpectomy with negative surgical margins and 0 to 3 positive axillary nodes without extracapsular extension. The APBI dose delivered was 34 Gy in 10 twice-daily fractions over 5 days for high-dose-rate (HDR); and 45 Gy in 3.5 to 5 days for low-dose-rate (LDR) brachytherapy. The primary endpoint was HDR and LDR MCT reproducibility. This analysis focuses on long-term ipsilateral breast recurrence (IBR), contralateral breast cancer events (CBE), regional recurrence (RR), and distant metastases (DM), disease-free, and overall survival. Results The median follow-up was 12.1 years. One hundred patients were accrued from 1997 to 2000; 98 were evaluable; 65 underwent HDR and 33 LDR MCT. Median age was 62 years; 88% had T1 tumors; 81% were pN0. Seventy-seven percent were estrogen receptor and/or progesterone receptor positive; 33% received adjuvant chemotherapy and 64% antiendocrine therapy. There have been 4 isolated IBRs and 1 IBR with RR, for 5.2% 10-year IBR without DM. There was 1 isolated RR, 1 with IBR, and 1 with a CBE, for 3.1% 10-year RR without DM. The 10-year CBE rate was 4.2%, with 5 total events. Eleven patients have developed DM, 8 have died of breast cancer, and 22 have died from other causes. The 10-year DFS and OS rates are 69.8% and 78.0%, respectively. Conclusion This multi-institutional, phase 2 trial studying MCT-APBI continues to report durable in-breast cancer control rates with long-term follow-up. To examine 10-year rates of local, regional, and distant recurrences, patterns of recurrence, and survival rates for breast cancer patients enrolled on Study NRG Oncology/Radiation Therapy Oncology Group 9517, a multi-institutional prospective trial that studied one of the earliest methods of accelerated partial breast irradiation (APBI), multicatheter brachytherapy (MCT). Eligibility included stage I/II unifocal breast cancer <3 cm in size after lumpectomy with negative surgical margins and 0 to 3 positive axillary nodes without extracapsular extension. The APBI dose delivered was 34 Gy in 10 twice-daily fractions over 5 days for high-dose-rate (HDR); and 45 Gy in 3.5 to 5 days for low-dose-rate (LDR) brachytherapy. The primary endpoint was HDR and LDR MCT reproducibility. This analysis focuses on long-term ipsilateral breast recurrence (IBR), contralateral breast cancer events (CBE), regional recurrence (RR), and distant metastases (DM), disease-free, and overall survival. The median follow-up was 12.1 years. One hundred patients were accrued from 1997 to 2000; 98 were evaluable; 65 underwent HDR and 33 LDR MCT. Median age was 62 years; 88% had T1 tumors; 81% were pN0. Seventy-seven percent were estrogen receptor and/or progesterone receptor positive; 33% received adjuvant chemotherapy and 64% antiendocrine therapy. There have been 4 isolated IBRs and 1 IBR with RR, for 5.2% 10-year IBR without DM. There was 1 isolated RR, 1 with IBR, and 1 with a CBE, for 3.1% 10-year RR without DM. The 10-year CBE rate was 4.2%, with 5 total events. Eleven patients have developed DM, 8 have died of breast cancer, and 22 have died from other causes. The 10-year DFS and OS rates are 69.8% and 78.0%, respectively. This multi-institutional, phase 2 trial studying MCT-APBI continues to report durable in-breast cancer control rates with long-term follow-up." @default.
• W2325814882 created "2016-06-24" @default.
• W2325814882 creator A5001197060 @default.
• W2325814882 creator A5016407136 @default.
• W2325814882 creator A5031160818 @default.
• W2325814882 creator A5032257865 @default.
• W2325814882 creator A5038635004 @default.
• W2325814882 creator A5043086504 @default.
• W2325814882 creator A5057121108 @default.
• W2325814882 creator A5062040958 @default.
• W2325814882 creator A5067136545 @default.
• W2325814882 creator A5074426228 @default.
• W2325814882 creator A5090146209 @default.
• W2325814882 date "2016-08-01" @default.
• W2325814882 modified "2023-09-25" @default.
• W2325814882 title "Long-Term Cancer Outcomes From Study NRG Oncology/RTOG 9517: A Phase 2 Study of Accelerated Partial Breast Irradiation With Multicatheter Brachytherapy After Lumpectomy for Early-Stage Breast Cancer" @default.
• W2325814882 cites W1967997207 @default.
• W2325814882 cites W1968755601 @default.
• W2325814882 cites W1968817519 @default.
• W2325814882 cites W1988186763 @default.
• W2325814882 cites W2083825568 @default.
• W2325814882 cites W2096499183 @default.
• W2325814882 cites W2098560759 @default.
• W2325814882 cites W2105839295 @default.
• W2325814882 cites W2122199930 @default.
• W2325814882 cites W2138602543 @default.
• W2325814882 cites W2146227526 @default.
• W2325814882 cites W2146522000 @default.
• W2325814882 cites W2151019069 @default.
• W2325814882 cites W2151707702 @default.
• W2325814882 cites W2178502550 @default.
• W2325814882 cites W2464041512 @default.
• W2325814882 cites W4293241248 @default.
• W2325814882 doi "https://doi.org/10.1016/j.ijrobp.2016.03.037" @default.
• W2325814882 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5088493" @default.
• W2325814882 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27479725" @default.
• W2325814882 hasPublicationYear "2016" @default.
• W2325814882 type Work @default.
• W2325814882 sameAs 2325814882 @default.
• W2325814882 citedByCount "45" @default.
• W2325814882 countsByYear W23258148822017 @default.
• W2325814882 countsByYear W23258148822018 @default.
• W2325814882 countsByYear W23258148822019 @default.
• W2325814882 countsByYear W23258148822020 @default.
• W2325814882 countsByYear W23258148822021 @default.
• W2325814882 countsByYear W23258148822022 @default.
• W2325814882 countsByYear W23258148822023 @default.
• W2325814882 crossrefType "journal-article" @default.
• W2325814882 hasAuthorship W2325814882A5001197060 @default.
• W2325814882 hasAuthorship W2325814882A5016407136 @default.
• W2325814882 hasAuthorship W2325814882A5031160818 @default.
• W2325814882 hasAuthorship W2325814882A5032257865 @default.
• W2325814882 hasAuthorship W2325814882A5038635004 @default.
• W2325814882 hasAuthorship W2325814882A5043086504 @default.
• W2325814882 hasAuthorship W2325814882A5057121108 @default.
• W2325814882 hasAuthorship W2325814882A5062040958 @default.
• W2325814882 hasAuthorship W2325814882A5067136545 @default.
• W2325814882 hasAuthorship W2325814882A5074426228 @default.
• W2325814882 hasAuthorship W2325814882A5090146209 @default.
• W2325814882 hasBestOaLocation W23258148822 @default.
• W2325814882 hasConcept C121608353 @default.
• W2325814882 hasConcept C126322002 @default.
• W2325814882 hasConcept C126838900 @default.
• W2325814882 hasConcept C143998085 @default.
• W2325814882 hasConcept C146357865 @default.
• W2325814882 hasConcept C151730666 @default.
• W2325814882 hasConcept C203092338 @default.
• W2325814882 hasConcept C2777416452 @default.
• W2325814882 hasConcept C2777757722 @default.
• W2325814882 hasConcept C2779494622 @default.
• W2325814882 hasConcept C2779572924 @default.
• W2325814882 hasConcept C2989005 @default.
• W2325814882 hasConcept C509974204 @default.
• W2325814882 hasConcept C530470458 @default.
• W2325814882 hasConcept C535046627 @default.
• W2325814882 hasConcept C71924100 @default.
• W2325814882 hasConcept C86803240 @default.
• W2325814882 hasConceptScore W2325814882C121608353 @default.
• W2325814882 hasConceptScore W2325814882C126322002 @default.
• W2325814882 hasConceptScore W2325814882C126838900 @default.
• W2325814882 hasConceptScore W2325814882C143998085 @default.
• W2325814882 hasConceptScore W2325814882C146357865 @default.
• W2325814882 hasConceptScore W2325814882C151730666 @default.
• W2325814882 hasConceptScore W2325814882C203092338 @default.
• W2325814882 hasConceptScore W2325814882C2777416452 @default.
• W2325814882 hasConceptScore W2325814882C2777757722 @default.
• W2325814882 hasConceptScore W2325814882C2779494622 @default.
• W2325814882 hasConceptScore W2325814882C2779572924 @default.
• W2325814882 hasConceptScore W2325814882C2989005 @default.
• W2325814882 hasConceptScore W2325814882C509974204 @default.
• W2325814882 hasConceptScore W2325814882C530470458 @default.
• W2325814882 hasConceptScore W2325814882C535046627 @default.
• W2325814882 hasConceptScore W2325814882C71924100 @default.
• W2325814882 hasConceptScore W2325814882C86803240 @default.
• W2325814882 hasIssue "5" @default.
• W2325814882 hasLocation W23258148821 @default.
• W2325814882 hasLocation W23258148822 @default.
• W2325814882 hasLocation W23258148823 @default.

• next